CD52 Overview
Molecule Name
CAMPATH-1 antigen
Synonyms
CDW52,HE5,CD52,CAMPATH-1 antigen
Drug Development Progress
Drugs in Clinical Trials5
Approved Drugs1
Highest Development StageApproved
Target Synonym
Epididymis Secretory Sperm Binding Protein Li 171mP，CD52 Antigen (CAMPATH-1 Antigen)，Epididymal Secretory Protein E5，He5，CDW52 Antigen (CAMPATH-1 Antigen)，CD52 Antigen，HEL-S-171mP，EDDM5，CD52，CDw52，Cambridge pathology 1 antigen，Human epididymis-specific protein 5，CAMPATH-1 antigen，CD52 Molecule
Background
CAMPATH-1 antigen, also known as cluster of differentiation 52 (CD52), is a glycoprotein that in humans is encoded by the CD52 gene.It is widely expressed on the cell surface of immune cells, such as mature lymphocytes, natural killer cells (NK), eosinophils, neutrophils, monocytes/macrophages, and dendritic cells (DCs).ligation of cell surface CD52 molecules may offer costimulatory signals for T-cell activation and proliferation.
CD52 Product List
You Have Viewed 0 Of 0 Results
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Alemtuzumab biosimilar (Zhangjiang Biotechnology) | Phase 2 Clinical | Shanghai Zhangjiang Biotechnology Co Ltd | Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
| ALLO-647 | ALLO-647 | Phase 2 Clinical | Allogene Therapeutics Inc | Carcinoma, Renal Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Multiple Myeloma | Details |
| Alemtuzumab Biosimilars(Cellectis) | CLLS-52; CLLS52 | Phase 2 Clinical | Cellectis Sa | Leukemia, Myeloid, Acute; Lymphoma, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details |
| Recombinant anti-CD52 humanized monoclonal antibody (Lanzhou Institute Of Biological Products/Shanghai Taiyin Biotechnology) | Phase 1 Clinical | Lanzhou Institute Of Biological Products Co Ltd, Shanghai Taiyin Biotechnology Co Ltd | Leukemia, B-Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Prolymphocytic; Leukemia, Prolymphocytic, T-Cell; Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell | Details | |
| Alemtuzumab biosimilar(BioXpress) | BX-1523; BXT-1523 | Clinical | Bioxpress Therapeutics Sa | Leukemia, B-Cell; Multiple Sclerosis | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Alemtuzumab | LDP-03; GZ-402673 | Approved | Bayer AG, Genzyme Corp | Campath, Lemtrada, MabCampath | United States | Multiple Sclerosis | Genzyme Corp | 2001-05-07 | Anemia, Aplastic; Anemia, Sickle Cell; Bone marrow transplant rejection; Diabetes Mellitus, Type 1; Fallopian Tube Neoplasms; Graft Rejection; Graft vs Host Disease; Hematologic Neoplasms; Hodgkin Disease; Kidney Diseases; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Leukemia, Prolymphocytic, T-Cell; Leukemia, T-Cell; Leukemia-Lymphoma, Adult T-Cell; Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peripheral; Lymphoproliferative Disorders; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Mycosis Fungoides; Myelodysplastic Syndromes; Myositis, Inclusion Body; Ovarian Neoplasms; Pancytopenia; Peritoneal Neoplasms; Rejection of renal transplantation; Sezary Syndrome; Waldenstrom Macroglobulinemia | Details |